Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Collaboration by Year
Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M) ($M)
Merck Collaboration: $256M in FY2025, up 4.9% from a year earlier.
Latest, FY2025
256
Period ended Dec 31, 2025
Change on a year earlier
+4.9%
244 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 256 | +4.9% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 244 | +8.9% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 224 | +6.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 210 | -50.5% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 424 | +116.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 196 | +4.3% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 188 | – | Form 10-K (filed 2022-02-25) ↗ |
Breakdown
What makes up collaboration
- Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Current receivables from partner ($M)167 · FY2025
- Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Current payables / liabilities to partner ($M)81 · FY2025
- Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Cost of sales profit-sharing & manufacturing ($M)256 · FY2025
- Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Net R&D cost-sharing expense ($M)56 · FY2025
- Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Commercialization / SG&A expense sharing ($M)97 · FY2025
- Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Intangible asset amortization in Cost of Sales ($M)153 · FY2021
Cite this data
StockData. (2026). Merck Collaboration ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-bayer
See every metric in the Merck KPI table. Data updated Oct 26, 2026.